Markets:

Overview

News

Currencies

International

Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

42.67 -1.07 (-2.45%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckMate -9ER Analysis Presented at ESMO 2021

September 16, 2021

From Exelixis, Inc.

Via Business Wire

2 Top Biotech Stocks to Buy Right Now ↗

September 11, 2021

Both have underperformed the market recently. And both are primed for a comeback.

Via The Motley Fool

Exelixis Statement on the Passing of Two Senior Executives

September 06, 2021

From Exelixis, Inc.

Via Business Wire

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗

July 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...

Via Benzinga

Is Exelixis Stock a Buy? ↗

September 02, 2021

This biotech stock is down, but it's not out just yet.

Via The Motley Fool

Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September

September 01, 2021

From Exelixis, Inc.

Via Business Wire

Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer ↗

August 26, 2021

Exelixis Inc's (NASDAQ: EXEL) collaborating partner Takeda Pharmaceutical Co Ltd (NYSE: TAK) and Ono Pharmaceutical Co Ltd have received...

Via Benzinga

Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

August 25, 2021

From Exelixis, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 17, 2021

Gainers Celularity (NASDAQ:CELU) shares rose 7.0% to $7.33 during Tuesday's after-market session. The market value of their outstanding shares is at $904.9...

Via Benzinga

Exelixis, Invenra Expand Oncology Pact ↗

August 16, 2021

Exelixis Inc (NASDAQ: EXEL) and Invenra have expanded their discovery and licensing collaboration to include 20 additional oncology targets. The augmented...

Via Benzinga

Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology

August 16, 2021

From Exelixis, Inc.

Via Business Wire

Exelixis, inc (EXEL) Q2 2021 Earnings Call Transcript ↗

August 06, 2021

EXEL earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Recap: Exelixis Q2 Earnings ↗

August 05, 2021

Shares of Exelixis (NASDAQ:EXEL) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 48.00% year over year...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

August 05, 2021

Gainers Sensus Healthcare (NASDAQ:SRTS) ...

Via Benzinga

Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update

August 05, 2021

From Exelixis, Inc.

Via Business Wire

Exelixis Files US Application For Expanded Use Of Cabometyx In Patients 12+ Years With Thyroid Cancer ↗

August 05, 2021

The FDA has accepted Exelixis Inc's (NASDAQ: EXEL) supplemental marketing application seeking approval for Cabometyx (cabozantinib) for differentiated thyroid...

Via Benzinga

Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

August 05, 2021

From Exelixis, Inc.

Via Business Wire

5 No-Brainer Stocks to Invest $500 In Right Now ↗

July 26, 2021

You don't need a mountain of cash to build wealth on Wall Street.

Via The Motley Fool

Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021

July 22, 2021

From Exelixis, Inc.

Via Business Wire

The Smartest Stocks to Buy With $20 in July ↗

July 16, 2021

You don't need a lot of cash to begin or further your trek toward financial independence.

Via The Motley Fool

Analyzing Exelixis's Unusual Options Activity ↗

July 12, 2021

Shares of Exelixis (NASDAQ:EXEL) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved down to $17.64. Sentiment: BULLISH Option...

Via Benzinga

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street ↗

July 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated...

Via Benzinga

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study ↗

July 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15) IVERIC bio, Inc. (NASDAQ:...

Via Benzinga

Topics Stocks

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs ↗

July 15, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals,...

Via Benzinga

Topics Product Recall

Stocks That Hit 52-Week Lows On Wednesday ↗

July 14, 2021

Wednesday morning saw 57 companies set new 52-week lows. Noteworthy Points: Campbell Soup (NYSE:CPB) was the largest firm by market cap to set a new 52-week low....

Via Benzinga

After Plummeting More Than 23%, Is Exelixis a Buy? ↗

July 09, 2021

The market may have overreacted to weak clinical trial data, but its pessimism wasn't entirely misplaced.

Via The Motley Fool

The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO ↗

July 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc...

Via Benzinga

Is Exelixis Stock a Buy After Its Disappointing Liver Cancer Study Results? ↗

July 09, 2021

The biotech stock plunged after disappointing clinical results.

Via The Motley Fool

Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021

July 08, 2021

From Exelixis, Inc.

Via Business Wire

The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test ↗

July 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:...

Via Benzinga

Topics Product Recall

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Exelixis, Inc. - Common Stock (NQ:EXEL)

All News about Exelixis, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today